Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Fulton

Allergy & Immunology Fort Collins, CO Medical Doctor

NPI 1346521887 CMS profile 288116

2121 E Harmony Rd, 350, Fort Collins, CO 80528

Open in the dashboard

General payments

$21,204

793 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$345,289 paid to institutions, not to them · program years 2023–2025

Through program year 2025, James Fulton of Fort Collins, CO is reported in the CMS Open Payments database as having received $21,204 across 793 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $345,289 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,874 174
2024 General $4,547 144
2023 General $4,212 133
2022 General $2,891 111
2021 General $2,039 103
2020 General $2,811 83
2019 General $830 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Fulton
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to James Fulton were reported at $3,874. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year James Fulton Allergy & Immunology median Middle half National median
2019 $830 $594 $163–$1,512 $163
2020 $2,811 $426 $106–$1,233 $114
2021 $2,039 $638 $157–$1,708 $132
2022 $2,891 $790 $205–$1,961 $149
2023 $4,212 $852 $220–$2,147 $160
2024 $4,547 $865 $203–$2,267 $164
2025 $3,874 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $5,677 151 payments
  2. Genzyme Corporation $3,012 64 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $2,238 129 payments
  4. GlaxoSmithKline, LLC. $1,899 152 payments
  5. Adare Pharmaceuticals, Inc. $1,515 7 payments
  6. CSL Behring $1,113 43 payments
  7. BioCryst US Sales Co., LLC $778 32 payments
  8. Genentech USA, Inc. $584 29 payments
  9. Regeneron Healthcare Solutions, Inc. $547 31 payments
  10. Amgen Inc. $519 19 payments
  11. Other $3,321 136 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,287 779 payments
  2. Travel and Lodging $2,264 7 payments
  3. Consulting Fee $1,515 3 payments
  4. Education $137 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $3,707 97 payments
  2. TEZSPIRE $3,477 59 payments
  3. CUVITRU $1,071 66 payments
  4. NUCALA $1,022 63 payments
  5. Haegarda $859 33 payments
  6. Orladeyo $800 33 payments
  7. FASENRA Respiratory $783 32 payments
  8. HYQVIA $695 35 payments
  9. FASENRA Respiratory $621 28 payments
  10. Xolair $561 28 payments
  11. Other $6,211 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,047

Median for Allergy/ Immunology: 449

Drug cost

$282,200

Median for Allergy/ Immunology: $169,700

Branded share of claims

33.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 82 $70,423
Dupixent Syringe Dupilumab Brand 16 $60,883
Tezspire Tezepelumab-Ekko Brand 13 $56,035
Breo Ellipta Fluticasone/Vilanterol Brand 40 $24,247
Spiriva Respimat Tiotropium Bromide Brand 23 $19,938
Advair Hfa Fluticasone Propion/Salmeterol Brand 24 $14,955
Dulera Mometasone/Formoterol Brand 15 $8,666
Symbicort Budesonide/Formoterol Fumarate Brand 23 $7,430
Azelastine Hcl Generic 178 $6,985
Ipratropium Bromide Generic 112 $2,742

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$327,631

Of which drugs: $249,739

Medicare patients

192

Average age 72

Services billed

14,238

122 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 52%
Ischemic heart disease 20%
Depression 20%
Diabetes 17%
COPD 17%
Osteoporosis 16%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 15 4,663 $137,372

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $1,924
  • Amgen Inc. $94
$2,018 13 —
DUPIXENT
  • GENZYME CORPORATION $340
  • Regeneron Healthcare Solutions, Inc. $63
$403 16 —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $303
$303 — —
XOLAIR
  • Genentech USA, Inc. $183
  • Novartis Pharmaceuticals Corporation $74
$257 — 4,663
Haegarda
  • CSL Behring $180
$180 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

793 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record